#Japan #healthcare #Tokyo #Fujitsu #TriNetX

TriNetX and Fujitsu Join Forces in a Groundbreaking Venture

In a notable development, TriNetX, a leading provider of solutions in Real-World Data (RWD) and Real-World Evidence (RWE), has entered into a joint venture with Fujitsu, one of Japan's premier electronic patient records (EPR) providers. This partnership, named TriNetX Japan K.K., aims to revolutionize the landscape of healthcare in Japan by improving patients' access to life-changing medications.

Set to debut in February 2025, this initiative marks a pivotal step for integrating Japan into the global realm of data-driven medicine and healthcare innovation. With Japan sitting as the third-largest pharmaceutical market worldwide, it presents unparalleled opportunities for clinical research and drug development. The country’s rapidly aging population serves as an ideal research foundation for age-related diseases, such as cancer, cardiovascular health, and neurodegenerative disorders.

Aiming for Innovation

Gadi Lachman, the founding CEO of TriNetX, emphasized the significance of this venture, stating that since fully entering the Japanese market in 2022, TriNetX has empowered pharmaceutical companies and researchers with secure access to anonymous patient data while adhering to Japan’s stringent privacy regulations. He believes that this partnership with Fujitsu will forge new avenues in research and solidify Japan's standing in the global healthcare sector, facilitating essential therapies for patients.

The joint venture plans to integrate the TriNetX LIVE™ platform—a global network encompassing over 200 million patient records—with Fujitsu's cloud-based health solutions in Japan. This integration seeks to establish a seamless link between leading medical institutions and key players in the biow sciences, thus enabling researchers and pharmaceutical companies efficient access to extensive electronic health record (EHR) datasets. Such a change is poised to revolutionize clinical trials and initiatives centered on precision medicine.

Futuristic Goals with Fujitsu

Fujitsu’s involvement is crucial, as expressed by Tatsuki Araki, head of the ‘Healthy Life’ division at Fujitsu. He highlighted their ambition of driving healthcare and bioscience innovations in Japan, creating an environment where previously underutilized medical data can efficiently contribute to clinical research. This venture aligns with Fujitsu's strategic business model, Fujitsu Uvance, which focuses on solving social issues, such as reducing medication gaps in Japan and crafting a society wherein everyone can select treatments that best suit their needs through a data-utilizing ecosystem.

The prolific growth of Japanese medical institutions joining the TriNetX network has already spurred researchers to conduct novel studies leveraging TriNetX's data and technology. Furthermore, pharmaceutical companies are increasingly recognizing these institutions' potential in facilitating clinical trials.

Leadership and Future Directions

Shogo Wakabayashi, the country manager for TriNetX Japan, will be leading the new entity, TriNetX Japan K.K. Meanwhile, Steve Kundrot, Chief Operating Officer, and Elizabeth Schwert, Vice President of Marketing and Business Development, will serve on its board of directors, guiding this innovative collaboration.

About TriNetX

TriNetX is an extensive network comprising healthcare organizations and bioscience companies dedicated to enhancing real-world research and expediting the development of new therapies. Through its compliant platform, TriNetX has enabled its global community to optimize clinical trial protocol designs, streamline trial operations, enhance safety signal detection, and enrich evidence generation.

More information can be found on TriNetX’s official website TriNetX.

About Fujitsu

Committed to creating a sustainable world through innovative solutions, Fujitsu operates as the digital transformation partner for clients across over 100 countries. The company aims to address significant global challenges through its extensive service offerings, which leverage core technologies such as computing, networking, AI, and data security. Fujitsu Limited reported a consolidated revenue of 3.7 trillion yen (approximately 26 billion USD) for the fiscal year ending March 31, 2024.
For more about Fujitsu, visit Fujitsu.